• 18466 Citations
  • 69 Scopus h-Index
1976 …2019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1985 2019

2019
1 Citation (Scopus)

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study

Luo, Y. H., Luo, L., Wampfler, J. A., Wang, Y., Liu, D., Chen, Y. M., Adjei, A., Midthun, D. E. & Yang, P., Aug 1 2019, In : The Lancet Oncology. 20, 8, p. 1098-1108 11 p.

Research output: Contribution to journalArticle

Open Access
Advisory Committees
Observational Studies
Lung Neoplasms
Cohort Studies
Survival

Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies

Xie, H. & Adjei, A., Mar 1 2019, In : Journal of Thoracic Oncology. 14, 3, p. 358-376 19 p.

Research output: Contribution to journalReview article

Thorax
Drug Therapy
Antibodies
Neoplasms
Pharmaceutical Preparations

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

Xie, H., Yin, J., Shah, M. H., Menefee, M. E., Bible, K. C., Reidy-Lagunes, D., Kane, M. A., Quinn, D. I., Gandara, D. R., Erlichman, C. & Adjei, A., Jan 1 2019, In : Investigational New Drugs.

Research output: Contribution to journalArticle

Gossypol
Adrenocortical Carcinoma
Troponin
Hypokalemia
B-Cell Lymphoma

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce

Friedberg, J. S., Culligan, M. J., Tsao, A. S., Rusch, V., Sepesi, B., Pass, H. I., Bueno, R., Burt, B., Sugarbaker, D. J., de Perrot, M., Adjei, A., Adusumilli, P. S., Hirsch, F. R., Malik, S. M. & Harpole, D. J., Aug 1 2019, In : Journal of Thoracic Oncology. 14, 8, p. 1343-1353 11 p.

Research output: Contribution to journalReview article

Joints
Mesothelioma
Lung
Research
Neoplasms
33 Citations (Scopus)

Control of confounding and reporting of results in causal inference studies

Lederer, D. J., Bell, S. C., Branson, R. D., Chalmers, J. D., Marshall, R., Maslove, D. M., Ost, D. E., Punjabi, N. M., Schatz, M., Smyth, A. R., Stewart, P. W., Suissa, S., Adjei, A., Akdis, C. A., Azoulay, É., Bakker, J., Ballas, Z. K., Bardin, P. G., Barreiro, E., Bellomo, R. & 28 others, Bernstein, J. A., Brusasco, V., Buchman, T. G., Chokroverty, S., Collop, N. A., Crapo, J. D., Fitzgerald, D. A., Hale, L., Hart, N., Herth, F. J., Iwashyna, T. J., Jenkins, G., Kolb, M., Marks, G. B., Mazzone, P., Moorman, J. R., Murphy, T. M., Noah, T. L., Reynolds, P., Riemann, D., Russell, R. E., Sheikh, A., Sotgiu, G., Swenson, E. R., Szczesniak, R., Szymusiak, R., Teboul, J. L. & Vincent, J. L., Jan 1 2019, In : Annals of the American Thoracic Society. 16, 1, p. 22-28 7 p.

Research output: Contribution to journalReview article

Critical Care
Causality
Sleep
Epidemiology
Research Design

Current Diagnosis and Management of Small-Cell Lung Cancer

Wang, S., Zimmermann, S., Parikh, K., Mansfield, A. & Adjei, A., Aug 1 2019, In : Mayo Clinic proceedings. 94, 8, p. 1599-1622 24 p.

Research output: Contribution to journalReview article

Open Access
Small Cell Lung Carcinoma
Immunotherapy
Cranial Irradiation
Topotecan
Carboplatin

Lung Cancer Worldwide

Adjei, A., Jun 1 2019, In : Journal of Thoracic Oncology. 14, 6, 1 p.

Research output: Contribution to journalEditorial

Lung Neoplasms

Pathologic Considerations and Standardization in Mesothelioma Clinical Trials

Tsao, M. S., Carbone, M., Galateau-Salle, F., Moreira, A. L., Nicholson, A. G., Roden, A., Adjei, A., Aubry, M. C., Fennell, D. A., Gomez, D., Harpole, D., Hesdorffer, M., Hirsch, F. R., Liu, G., Malik, S., Nowak, A., Peikert, T. D., Salgia, R., Szlosarek, P., Taioli, E. & 3 others, Yang, H., Tsao, A. & Mansfield, A., Jan 1 2019, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

Mesothelioma
Clinical Trials
National Cancer Institute (U.S.)
Pleura
Specimen Handling

Progress in the Diagnosis and Treatment of Thoracic Malignancies Continues Unabated

Adjei, A., May 1 2019, In : Journal of Thoracic Oncology. 14, 5, 1 p.

Research output: Contribution to journalEditorial

Thorax
Neoplasms
1 Citation (Scopus)

Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?

Duma, N., Abdel-Ghani, A., Yadav, S., Hoversten, K. P., Reed, C. T., Sitek, A. N., Enninga, E. A. L., Paludo, J., Aguilera, J. V., Leventakos, K., Lou, Y., Kottschade, L. A., Dong, H. M., Mansfield, A., Manochakian, R., Adjei, A. & Dronca, R. S., Jan 1 2019, In : Oncologist.

Research output: Contribution to journalArticle

Programmed Cell Death 1 Receptor
Non-Small Cell Lung Carcinoma
Sex Characteristics
Melanoma
Therapeutics

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Gomez, D. R., Rimner, A., Simone, C. B., Cho, B. C. J., de Perrot, M., Adjei, A., Bueno, R., Gill, R. R., Harpole, D. H., Hesdorffer, M., Hirsch, F. R., Jackson, A. A., Pass, H. I., Rice, D. C., Rusch, V. W., Tsao, A. S., Yorke, E. & Rosenzweig, K., Jul 1 2019, In : Journal of Thoracic Oncology. 14, 7, p. 1172-1183 12 p.

Research output: Contribution to journalReview article

Open Access
National Cancer Institute (U.S.)
Mesothelioma
Expert Testimony
Radiotherapy
Thorax
2018

2017—A Banner Year for Thoracic Oncology

Adjei, A., Mar 1 2018, In : Journal of Thoracic Oncology. 13, 3, p. e33-e34

Research output: Contribution to journalEditorial

Thorax
1 Citation (Scopus)

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib with Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients

Ma, W. W., Xie, H., Fetterly, G., Pitzonka, L., Whitworth, A., Levea, C., Wilton, J., Mantione, K., Schihl, S., Dy, G. K., Boland, P., Iyer, R., Tan, W., Brady, W., Straubinger, R. M. & Adjei, A., Jan 1 2018, (Accepted/In press) In : American Journal of Clinical Oncology: Cancer Clinical Trials.

Research output: Contribution to journalArticle

gemcitabine
Pancreatic Neoplasms
Maximum Tolerated Dose
Neoplasms
Biliary Tract Neoplasms
tipifarnib
Farnesyltranstransferase
Epidermal Growth Factor
Protein-Tyrosine Kinases
Maximum Tolerated Dose
Pemetrexed
Vascular Endothelial Growth Factor A
Maximum Tolerated Dose
Neoplasms
Proto-Oncogene Proteins c-kit
Pharmacokinetics
Protein-Tyrosine Kinases
Appointments and Schedules
Safety
Maximum Tolerated Dose

Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer

Goyal, G., Kommalapati, A., Bartley, A. C., Gunderson, T. M., Adjei, A. & Go, R. S., Aug 1 2018, In : Lung Cancer. 122, p. 214-219 6 p.

Research output: Contribution to journalArticle

Hospital Mortality
Non-Small Cell Lung Carcinoma
Survival
Mortality
Survival Analysis
2 Citations (Scopus)

Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations

Le-Rademacher, J., Dahlberg, S., Lee, J. J., Adjei, A. & Mandrekar, S. J., Nov 1 2018, In : Journal of Thoracic Oncology. 13, 11, p. 1625-1637 13 p.

Research output: Contribution to journalReview article

Lung Neoplasms
Biomarkers
Clinical Trials
Precision Medicine
Standard of Care

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

Duma, N., Kothadia, S. M., Azam, T. U., Yadav, S., Paludo, J., Vera Aguilera, J., Gonzalez Velez, M., Halfdanarson, T. R., Molina, J. R., Hubbard, J. M., Go, R. S., Mansfield, A. & Adjei, A., Jan 1 2018, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Patient Selection
Comorbidity
Clinical Trials
Central Nervous System
Neoplasm Metastasis
8 Citations (Scopus)

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Tsao, A. S., Lindwasser, O. W., Adjei, A., Adusumilli, P. S., Beyers, M. L., Blumenthal, G. M., Bueno, R., Burt, B. M., Carbone, M., Dahlberg, S. E., de Perrot, M., Fennell, D. A., Friedberg, J., Gill, R. R., Gomez, D. R., Harpole, D. H., Hassan, R., Hesdorffer, M., Hirsch, F. R., Hmeljak, J. & 21 others, Kindler, H. L., Korn, E. L., Liu, G., Mansfield, A., Nowak, A. K., Pass, H. I., Peikert, T. D., Rimner, A., Robinson, B. W. S., Rosenzweig, K. E., Rusch, V. W., Salgia, R., Sepesi, B., Simone, C. B., Sridhara, R., Szlosarek, P., Taioli, E., Tsao, M. S., Yang, H., Zauderer, M. G. & Malik, S. M., Nov 1 2018, In : Journal of Thoracic Oncology. 13, 11, p. 1655-1667 13 p.

Research output: Contribution to journalArticle

National Cancer Institute (U.S.)
Mesothelioma
Thorax
Clinical Trials
Research
10 Citations (Scopus)

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy

Yan, Y., Cao, S., Liu, X., Harrington, S. M., Bindeman, W. E., Adjei, A., Jang, J. S., Jen, J., Li, Y., Chanana, P., Mansfield, A., Park, S. S., Markovic, S. N., Dronca, R. S. & Dong, H. M., Apr 19 2018, In : JCI insight. 3, 8

Research output: Contribution to journalArticle

Open Access
T-Lymphocytes
Drug Therapy
Aptitude
Neoplasms
Therapeutics
17 Citations (Scopus)

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Moschos, S. J., Sullivan, R. J., Hwu, W. J., Ramanathan, R. K., Adjei, A., Fong, P. C., Shapira-Frommer, R., Tawbi, H. A., Rubino, J., Rush, T. S., Zhang, D., Miselis, N. R., Samatar, A. A., Chun, P., Rubin, E. H., Schiller, J., Long, B. J., Dayananth, P., Carr, D., Kirschmeier, P. & 8 others, Bishop, W. R., Deng, Y., Cooper, A., Shipps, G. W., Moreno, B. H., Robert, L., Ribas, A. & Flaherty, K. T., Feb 22 2018, In : JCI insight. 3, 4

Research output: Contribution to journalArticle

Open Access
Neoplasms
Melanoma
Clinical Trials, Phase I
Exanthema
Heterografts
8 Citations (Scopus)

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

Soyano, A. E., Dholaria, B., Marin-Acevedo, J. A., Diehl, N., Hodge, D., Luo, Y., Manochakian, R., Chumsri, S., Adjei, A., Knutson, K. L. & Lou, Y., Nov 23 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 129.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Cell Death
Lymphocyte Count
Biomarkers
Neutrophils
13 Citations (Scopus)

Representation of minorities and women in oncology clinical trials: Review of the past 14 years

Duma, N., Aguilera, J. V., Paludo, J., Haddox, C. L., Velez, M. G., Wang, Y., Leventakos, K., Hubbard, J. M., Mansfield, A., Go, R. S. & Adjei, A., Jan 1 2018, In : Journal of Oncology Practice. 14, 1, p. e1-e10

Research output: Contribution to journalReview article

Clinical Trials
Hispanic Americans
African Americans
Neoplasms
Pancreatic Neoplasms
2 Citations (Scopus)

Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers

Lou, Y., Dholaria, B., Soyano, A., Hodge, D., Cochuyt, J., Manochakian, R., Ko, S. J., Thomas, M., Johnson, M. M., Patel, N. M., Miller, R. C., Adjei, A. & Ailawadhi, S., Jan 1 2018, (Accepted/In press) In : Cancer Medicine.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Survival
Therapeutics
Databases
Neoplasms

What is a “High-Impact” Journal?

Adjei, A., Jan 1 2018, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

2017
28 Citations (Scopus)
Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Drug Therapy
docetaxel
gemcitabine
5 Citations (Scopus)

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

Soria, J. C., Adjei, A., Bahleda, R., Besse, B., Ferte, C., Planchard, D., Zhou, J., Ware, J., Morrissey, K., Shankar, G., Lin, W., Schutzman, J. L., Dy, G. K. & Groen, H. J. M., Nov 1 2017, In : European Journal of Cancer. 86, p. 186-196 11 p.

Research output: Contribution to journalArticle

Pemetrexed
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Cisplatin
10 Citations (Scopus)

A phase I clinical trial and independent patient-derived xenograft study of combined targeted treatment with dacomitinib and figitumumab in advanced solid tumors

Calvo, E., Soria, J. C., Ma, W. W., Wang, T., Bahleda, R., Tolcher, A. W., Gernhardt, D., O'Connell, J., Millham, R., Giri, N., Wick, M. J., Adjei, A. & Hidalgo, M., Mar 1 2017, In : Clinical Cancer Research. 23, 5, p. 1177-1185 9 p.

Research output: Contribution to journalArticle

Clinical Trials, Phase I
Heterografts
Adenoid Cystic Carcinoma
Neoplasms
Therapeutics
9 Citations (Scopus)

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

Adjei, A., LoRusso, P., Ribas, A., Sosman, J. A., Pavlick, A., Dy, G. K., Zhou, X., Gangolli, E., Kneissl, M., Faucette, S., Neuwirth, R. & Bózon, V., Feb 1 2017, In : Investigational New Drugs. 35, 1, p. 47-58 12 p.

Research output: Contribution to journalArticle

Mitogen-Activated Protein Kinase Kinases
Neoplasms
Melanoma
Maximum Tolerated Dose
Phosphorylation
1 Citation (Scopus)

Avelumab: Another active immune checkpoint inhibitor in nonsmall cell lung cancer

Xie, H. & Adjei, A., Dec 1 2017, In : Translational Lung Cancer Research. 6, p. S41-S43

Research output: Contribution to journalEditorial

Non-Small Cell Lung Carcinoma
avelumab
21 Citations (Scopus)

First-in-human phase I Study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer

Goetz, M. P., Suman, V. J., Reid, J. M., Northfelt, D. W., Mahr, M. A., Ralya, A. T., Kuffel, M., Visscher, S. A., Kipp, B. R., Liu, M. C., Hawse, J. R., Ames, M. M., Ingle Buhrow, J. N., Safgren, S. L., McGovern, R. M., Black, J., Dockter, T., Haddad, T. C., Erlichman, C., Adjei, A. & 7 others, Collins, D., Streicher, H., Chalmers, Z. R., Frampton, G., Hawse, J. R., Doroshow, J. H. & Collins, J. M., Oct 20 2017, In : Journal of Clinical Oncology. 35, 30, p. 3391-3400 10 p.

Research output: Contribution to journalArticle

Tamoxifen
Breast Neoplasms
Maximum Tolerated Dose
Mutation
Cytochrome P-450 CYP2D6
6 Citations (Scopus)

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

Mayo Clinic, North Central Cancer Treatment Group, Apr 1 2017, In : Journal of Thoracic Oncology. 12, 4, p. 697-703 7 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Radiation
Drug Therapy
Radiotherapy
Maximum Tolerated Dose

Lung Cancer Awareness Month—A Lot of Progress, But More Work Needs to Be Done

Henningfield, M. F. & Adjei, A., Nov 1 2017, In : Journal of Thoracic Oncology. 12, 11, p. 1603-1605 3 p.

Research output: Contribution to journalEditorial

Lung Neoplasms
5 Citations (Scopus)

Management of Multifocal Lung Cancer: Results of a Survey

Leventakos, K., Peikert, T. D., Midthun, D. E., Molina, J. R., Blackmon, S., Nichols, F. C., Garces, Y. I., Hallemeier, C., Murphy, S. J., Vasmatzis, G., Kratz, S. L., Holland, W. P., Thomas, C. F., Mullon, J. J., Shen, K. R., Cassivi, S. D., Marks, R. S., Aubry, M. C., Adjei, A., Yang, P. & 4 others, Allen, M. S., Edell, E., Wigle, D. A. & Mansfield, A., 2017, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

Lung Neoplasms
Neoplasm Metastasis
Mediastinoscopy
Mediastinum
Bronchoscopy
2 Citations (Scopus)

Predicting Clinical Outcomes Using Proteomics in Non–Small Cell Lung Cancer—The Past, Present, and Future

Soo, R. A. & Adjei, A., Apr 1 2017, In : Journal of Thoracic Oncology. 12, 4, p. 602-606 5 p.

Research output: Contribution to journalEditorial

Non-Small Cell Lung Carcinoma
Proteomics
3 Citations (Scopus)

Quality-of-life (QOL) during screening for phase 1 trial studies in patients with advanced solid tumors and its impact on risk for serious adverse events

Anwar, S., Tan, W., Hong, C. C., Admane, S., Dozier, A., Siedlecki, F., Whitworth, A., Diraddo, A. M., DePaolo, D., Jacob, S. M., Ma, W. W., Miller, A., Adjei, A. & Dy, G. K., Jul 1 2017, In : Cancers. 9, 7, 73.

Research output: Contribution to journalArticle

Quality of Life
Social Support
Comorbidity
Neoplasms
Outcome Assessment (Health Care)

The Journal of Thoracic Oncology Achieves a New Benchmark

Adjei, A., Sep 1 2017, In : Journal of Thoracic Oncology. 12, 9, 1 p.

Research output: Contribution to journalEditorial

Benchmarking
Thorax
2 Citations (Scopus)

Validation of progression-free survival as a surrogate endpoint for overall survival inmalignant mesothelioma: Analysis of cancer and leukemia group B and north central cancer treatment group (Alliance) trials

Wang, X., Wang, X., Hodgson, L., George, S. L., Sargent, D. J., Foster, N. R., Ganti, A. K., Stinchcombe, T. E., Crawford, J., Kratzke, R., Adjei, A., Kindler, H. L., Vokes, E. E. & Pang, H., Feb 10 2017, In : Oncologist. 22, 2, p. 189-198 10 p.

Research output: Contribution to journalArticle

Mesothelioma
Disease-Free Survival
Leukemia
Biomarkers
Survival
2016
18 Citations (Scopus)

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

Rosen, L. S., LoRusso, P., Ma, W. W., Goldman, J. W., Weise, A., Colevas, A. D., Adjei, A., Yazji, S., Shen, A., Johnston, S., Hsieh, H. J., Chan, I. T. & Sikic, B. I., Oct 1 2016, In : Investigational New Drugs. 34, 5, p. 604-613 10 p.

Research output: Contribution to journalArticle

Neoplasms
Appointments and Schedules
Exanthema
Maximum Tolerated Dose
Pharmacokinetics
13 Citations (Scopus)

Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

Reungwetwattana, T. & Adjei, A., Jan 1 2016, In : Journal of Thoracic Oncology. 11, 12, p. 2048-2050 3 p.

Research output: Contribution to journalEditorial

Pulmonary Tuberculosis
Antibodies
6 Citations (Scopus)

A phase I study of the safety, Pharmacokinetics, and Pharmacodynamics of combination therapy with refametinib plus sorafenib in patients with advanced cancer

Adjei, A., Richards, D. A., El-Khoueiry, A., Braiteh, F., Becerra, C. H. R., Jr, J. J. S., Hezel, A. F., Sherman, M., Garbo, L., Leffingwell, D. P., Iverson, C., Miner, J. N., Shen, Z., Yeh, L. T., Gunawan, S., Wilson, D. M., Manhard, K. J., Rajagopalan, P., Krissel, H. & Clendeninn, N. J., May 15 2016, In : Clinical Cancer Research. 22, 10, p. 2368-2376 9 p.

Research output: Contribution to journalArticle

Maximum Tolerated Dose
Pharmacokinetics
Safety
Neoplasms
Therapeutics
69 Citations (Scopus)

Consensus report of the 2015 Weinman international conference on mesothelioma

Carbone, M., Kanodia, S., Chao, A., Miller, A., Wali, A., Weissman, D., Adjei, A., Baumann, F., Boffetta, P., Buck, B., De Perrot, M., Dogan, A. U., Gavett, S., Gualtieri, A., Hassan, R., Hesdorffer, M., Hirsch, F. R., Larson, D., Mao, W., Masten, S. & 8 others, Pass, H. I., Peto, J., Pira, E., Steele, I., Tsao, A., Woodard, G. A., Yang, H. & Malik, S., Jan 1 2016, In : Journal of Thoracic Oncology. 11, 8, p. 1246-1262 17 p.

Research output: Contribution to journalArticle

Asbestos
Mesothelioma
Mineral Fibers
BRCA1 Protein
Biomarkers
8 Citations (Scopus)

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways

Zhang, H., Shao, H., Golubovskaya, V. M., Chen, H., Cance, W., Adjei, A. & Dy, G. K., Jul 12 2016, In : British Journal of Cancer. 115, 2, p. 203-211 9 p.

Research output: Contribution to journalArticle

Focal Adhesion Protein-Tyrosine Kinases
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Epidermal Growth Factor Receptor
Mutation
32 Citations (Scopus)

Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012

Pang, H. H., Wang, X., Stinchcombe, T. E., Wong, M. L., Cheng, P., Ganti, A. K., Sargent, D. J., Zhang, Y., Hu, C., Mandrekar, S. J., Redman, M. W., Manola, J. B., Schilsky, R. L., Cohen, H. J., Bradley, J. D., Adjei, A., Gandara, D., Ramalingam, S. S. & Vokes, E. E., Nov 20 2016, In : Journal of Clinical Oncology. 34, 33, p. 3992-3999 8 p.

Research output: Contribution to journalArticle

Lung Neoplasms
Clinical Trials
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Population
27 Citations (Scopus)

FGFR signaling as a target for Lung cancer therapy

Desai, A. & Adjei, A., Jan 1 2016, In : Journal of Thoracic Oncology. 11, 1, p. 9-20 12 p.

Research output: Contribution to journalReview article

Fibroblast Growth Factor Receptors
Lung Neoplasms
Molecular Targeted Therapy
Fibroblast Growth Factors
Therapeutics
44 Citations (Scopus)

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Arena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A., Montagut, C., Di Nicolantonio, F., Nering, R. & Bardelli, A., Feb 3 2016, In : Science Translational Medicine. 8, 324, 324ra14.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Colorectal Neoplasms
Mutation
Antibodies
Cetuximab
3 Citations (Scopus)

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

Manegold, C., Adjei, A., Bussolino, F., Cappuzzo, F., Crino, L., Dziadziuszko, R., Ettinger, D., Fennell, D., Kerr, K., Le Chevalier, T., Leighl, N., Papotti, M., Paz-Ares, L., Pérol, M., Peters, S., Pirker, R., Quoix, E., Reck, M., Smit, E., Vokes, E. & 2 others, Van Zandwijk, N. & Zhou, C., Dec 1 2016, In : ESMO Open. 1, 6, e000118.

Research output: Contribution to journalReview article

Proxy
Non-Small Cell Lung Carcinoma
Drug Therapy
Mutation
Therapeutics

The Journal of Thoracic Oncology in the next decade

Adjei, A., Jan 1 2016, In : Journal of Thoracic Oncology. 11, 1, 1 p.

Research output: Contribution to journalEditorial

Medical Oncology
Lung Neoplasms
Thorax
2015
147 Citations (Scopus)

2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer

Panel Members, Jan 1 2015, In : Annals of Oncology. 26, 8, p. 1573-1588 16 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Molecular Pathology
Neoplasms
Biomarkers